Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia, Functional Magnetic Resonance Imaging
Effect of Intermittent Theta Burst Stimulation (iTBS) for Alleviating Symptoms of Schizophrenia Patients
To investigate the treatment effect of intermittent theta-burst transcranial magnetic stimulation on symptomatic relief of schizophrenia patients, and the underlying neural mechanism by functional MRI and the resting…
- Conditions
- Schizophrenia, Functional Magnetic Resonance Imaging, Transcranial Magnetic Stimulation
- Trial name
- NCT03868358
- Testing
- transcranial magnetic stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- WANG KAI
Schizophrenia, Schizoaffective Disorder
Sustainable Early Episode Clinic Study (SEEC)
The purpose of this study is to describe relapse rates among participants receiving services in the SEEC program high intensity resource use.
- Trial name
- SEEC (NCT03571685)
- Testing
- Sustainable Early Episode Clinic Model of Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
- Trial name
- NCT05438160
- Testing
- Clinical Learning Study smartphone app (i.e., the study app)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Cognitive Remediation for Schizophrenia
The purpose of this study is to evaluate the efficacy of an innovative, computer driven cognitive rehabilitation program for individuals with schizophrenia and related disorders.
- Trial name
- NCT00295048
- Testing
- Computer Assisted Cognitive Remediation (CACR)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal…
- Trial name
- NCT00645515
- Testing
- Ziprasidone, Risperidone
- Where
- 3 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Effects of Gamified Rehabilitation on Cognitive and Psychosocial Outcomes in Inpatients With Schizophrenia
Schizophrenia is a severe and chronic mental disorder that profoundly impacts patients' psychological, social, and occupational functions. Cognitive impairment is a core symptom that severely limits daily living abilities.
- Trial name
- NCT07557368
- Testing
- Gamified Digital Rehabilitation
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
- Trial name
- NCT02634320
- Testing
- Aripiprazole Lauroxil
- Where
- 18 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizoaffective Disorder
Comparing Cognitive Remediation Approaches for Schizophrenia
This research compares the relative efficacy of two empirically-supported, standardized programs of cognitive remediation for treatment of cognitive deficits and community function in schizophrenia to help inform best practices.
- Trial name
- NCT04123223
- Testing
- Cognitive Remediation, Computer Games
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- Wesleyan University
Schizophrenia, Schizoaffective Disorder
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse
- Trial name
- NCT00156715
- Testing
- Quetiapine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or…
- Trial name
- NCT00100776
- Testing
- Olanzapine
- Where
- 33 sites in United States
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
Treatment of Neuroleptic Induced Acute Akathisia With Trazodone
Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.
- Trial name
- NCT00659919
- Testing
- Trazodone
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- BeerYaakov Mental Health Center
Schizophrenia
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
- Trial name
- STAR-1 (NCT07467993)
- Testing
- GXV813
- Where
- 16 sites in United States, Bulgaria
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
Schizophrenia is a heterogeneous mental disorder that affects one percent of the world's population. Current antipsychotics are only partially effective, and their use is often associated with serious side effects.
- Trial name
- NCT02088060
- Testing
- Cannabidiol, Olanzapine
- Where
- 6 sites in Denmark, Germany
- Volunteers
- 150 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Bipolar Disorder, Schizophrenia
fMRI of Theory of Mind in Schizophrenia and Bipolar Disorder
Theory of mind (TOM), a main component of social cognition processes, refers to the capacity to infer one's own and other person's mental states.
- Trial name
- TOM-i (NCT02834182)
- Testing
- IRMf, Mini International Neuropsychiatric Interview, Positive And Negative Syndrom Scale
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Schizophrenia, Schizoaffective
Treatment of Refractory Schizophrenia With Riluzole
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms.
- Trial name
- NCT00375050
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yale University
Schizophrenia
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make…
- Trial name
- NCT00742079
- Testing
- D-cycloserine, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Schizophrenia
eVAluatIon of OLanzapine TreatmEnT
This clinical observational study aims to investigate the efficacy of olanzapine (Villamos ®) in accordance with the instructions attached thereto in standard clinical practice, followed by the physician to the patient.
- Trial name
- VIOLET (NCT02006862)
- Where
- Greece
- Volunteers
- 468 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Psychosis
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
To demonstrate the relative bioequivalency of generic Haloperidol tablets versus Haldol in normal volunteers.
- Trial name
- NCT00946491
- Testing
- Haloperidol 10 mg Tablets (Cord Laboratories), Haldol 10 mg Tablets (McNeil Pharmaceuticals)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Schizophrenia
Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)
Cognition is one of the core symptoms of schizophrenia. This study is a head-to-head trial between olanzapine and sertindole with cognition as primary outcome.
- Trial name
- SEROLA (NCT00885690)
- Testing
- Sertindole, Olanzapine
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.